Doubts over BMS-Celgene merger after Starboard interventionDoubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key Share XDoubts over BMS-Celgene merger after Starboard interventionhttps://pharmaphorum.com/news/doubts-over-bms-celgene-merger-after-starboard-intervention/
Largest BMS shareholder opposes Celgene dealBristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future Share XLargest BMS shareholder opposes Celgene dealhttps://pharmaphorum.com/news/largest-bms-shareholder-opposes-celgene-deal/
Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
BMS pulls Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line Share XBMS pulls Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
2019 M&A starts with a bang as BMS and Celgene agree $74bn mergerBristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost Share X2019 M&A starts with a bang as BMS and Celgene agree $74bn mergerhttps://pharmaphorum.com/news/2019-ma-starts-with-a-bang-as-bms-agrees-74bn-merger-with-celgene/
BMS confirms Taisho’s $1.6bn offer for UPSAAfter protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA Share XBMS confirms Taisho’s $1.6bn offer for UPSAhttps://pharmaphorum.com/news/bms-confirms-taishos-1-6bn-offer-for-upsa/
BMS looks to RNA splicing to boost immunotherapiesBristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and Share XBMS looks to RNA splicing to boost immunotherapieshttps://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/
Pfizer might buy BMS for $130bn – but should it?Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields Share XPfizer might buy BMS for $130bn – but should it?https://pharmaphorum.com/news/pfizer-might-buy-bms-for-130bn-but-should-it/
